Real-World Treatment Outcomes of an Artificial Tear Containing Arabinogalactan, Hyaluronic Acid and Trehalose Among Subjects with Dry Eye

Andrea Bedei,1 Pedro Rocha Cabrera,2 Luis Oliveira,3 Laura Castellini,1 Giulia De Grazia,4 Stefano Remiddi4 1Ophthalmology Department Casa di Cura San Camillo, Forte dei Marmi, Italy; 2Ophthalmology Department Hospital San Juan de Dios Tenerife, Santa Cruz de Tenerife, Spain; 3Ophthalmology Department Hospital Santo Antonio, Porto, Portugal; 4Department of Research and Development, MD Italy, Albano Laziale, ItalyCorrespondence: Stefano Remiddi, MD Italy srl, Department of Research and Development, Via Cancelliera, 12, Albano Laziale, Rome, 00041, Italy, Email [email protected]: To assess the efficacy, adherence, and tolerability of a new artificial tear based on arabinogalactan, hyaluronic acid, and trehalose in a population with dry eye disease (DED).Methods: A retrospective, real-world, post-marketing study identified 96 adult patients (aged 18– 80 years) with signs and symptoms of dry eye. These patients received fixed combination therapy with eye drops containing arabinogalactan, hyaluronic acid, and trehalose at various dosing schedules. The data for this study were collected from April 2022 to June 2023. Patients underwent evaluation at baseline (T0) and after a follow-up period of two–three months (T1) using a patient-reported questionnaire.Results: In 96 adult patients (71 women and 25 men) with dry eye due to various conditions, the results indicated a 98% positive response to therapy. This response included improvements in vision (13%), comfort (39%), redness (13%), itching (16%), photophobia (4%), and tearing (14%). Additionally, 61% of the patients experienced 1– 2 hours of comfort following instillation.Conclusion: This real-life post-marketing study demonstrated clinical improvement of signs and symptoms in patients with dry eye disease using a new artificial tear medical device based on arabinogalactan, hyaluronic acid, and trehalose.Keywords: dry eye, real-world study, arabinogalactan, hyaluronic acid, trehalose, post-marketing study

Publication Details

Journal
SHILAP Revista de lepidopterología
Published
2025-01-01
Primary Topic
Aquatic Invertebrate Ecology and Behavior
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-World Treatment Outcomes of an Artificial Tear Containing Arabinogalactan, Hyaluronic Acid and Trehalose Among Subjects with Dry Eye

SHILAP Revista de lepidopterología
Aquatic Invertebrate Ecology and Behavior
article

Real-World Treatment Outcomes of an Artificial Tear Containing Arabinogalactan, Hyaluronic Acid and Trehalose Among Subjects with Dry Eye

article en

Abstract

Andrea Bedei,1 Pedro Rocha Cabrera,2 Luis Oliveira,3 Laura Castellini,1 Giulia De Grazia,4 Stefano Remiddi4 1Ophthalmology Department Casa di Cura San Camillo, Forte dei Marmi, Italy; 2Ophthalmology Department Hospital San Juan de Dios Tenerife, Santa Cruz de Tenerife, Spain; 3Ophthalmology Department Hospital Santo Antonio, Porto, Portugal; 4Department of Research and Development, MD Italy, Albano Laziale, ItalyCorrespondence: Stefano Remiddi, MD Italy srl, Department of Research and Development, Via Cancelliera, 12, Albano Laziale, Rome, 00041, Italy, Email [email protected]: To assess the efficacy, adherence, and tolerability of a new artificial tear based on arabinogalactan, hyaluronic acid, and trehalose in a population with dry eye disease (DED).Methods: A retrospective, real-world, post-marketing study identified 96 adult patients (aged 18– 80 years) with signs and symptoms of dry eye. These patients received fixed combination therapy with eye drops containing arabinogalactan, hyaluronic acid, and trehalose at various dosing schedules. The data for this study were collected from April 2022 to June 2023. Patients underwent evaluation at baseline (T0) and after a follow-up period of two–three months (T1) using a patient-reported questionnaire.Results: In 96 adult patients (71 women and 25 men) with dry eye due to various conditions, the results indicated a 98% positive response to therapy. This response included improvements in vision (13%), comfort (39%), redness (13%), itching (16%), photophobia (4%), and tearing (14%). Additionally, 61% of the patients experienced 1– 2 hours of comfort following instillation.Conclusion: This real-life post-marketing study demonstrated clinical improvement of signs and symptoms in patients with dry eye disease using a new artificial tear medical device based on arabinogalactan, hyaluronic acid, and trehalose.Keywords: dry eye, real-world study, arabinogalactan, hyaluronic acid, trehalose, post-marketing study

SHILAP Revista de lepidopterología
Openalex Percentile: Top 45%
Aquatic Invertebrate Ecology and Behavior
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Real-World Treatment Outcomes of an Artificial Tear Containing Arabinogalactan, Hyaluronic Acid and Trehalose Among Subjects with Dry Eye · SHILAP Revista de lepidopterología (2025) | TGRS Research Map | TGRS